Cooperative Agreement AID492A000600032

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $238,500 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program to the University of California, San Diego (UCSD) to develop a novel electrochemical lateral flow assay (ELFA) for diagnosing tuberculosis (TB) from a single drop of blood. The objective is to create a highly sensitive and specific point-of-need TB detection test that can accurately distinguish active TB from...

Federal Project Grant Award Summary Vanderbilt University Medical Center received a $1.17 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 3, 2025, with a completion date of August 31, 2030. This award funds research investigating pathogen and host predictors of Mycobacterium tuberculosis (M. tuberculosis) transmission through the well-established...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,141,359 Project Grant to The University of Texas Southwestern Medical Center on September 11, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This five-year research initiative, concluding August 31, 2030, investigates the mechanisms of Mycobacterium tuberculosis (MTB) transmission via airborne particles, with particular focus on host and bacterial...

National Jewish Health received a $429,546 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to evaluate antibiotic regimen efficacy for tuberculosis (TB) treatment. The award, effective August 8, 2025, through July 31, 2027, supports research utilizing SEARCH-TB, an RNA-sequencing platform designed to quantify drug-induced bacterial injury and physiological adaptations in Mycobacterium...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $927,025 to the Texas Biomedical Research Institute on May 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a project extending through April 30, 2031. This Project Grant funds research aimed at enhancing pulmonary immune reconstitution and limiting viral persistence through interleukin-21 (IL-21) therapy in individuals with combined Mycobacterium...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $842,888 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco on February 9, 2026. This Project Grant supports research to identify immunological and transcriptional factors associated with treatment outcomes in drug-susceptible tuberculosis (TB) patients. The research will define host immune pathways and genetic...

Federal Project Grant Award Summary Emory University received a $1,173,748 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 16, 2025 through August 31, 2030. The grant supports investigator-initiated research to advance understanding of tuberculosis (TB) transmission dynamics, specifically examining the infectiousness of asymptomatic TB cases and their...

Federal Project Grant Summary Oregon Health & Science University received a $743,817 Project Grant award from the National Institute of Allergy and Infectious Diseases under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 12, 2025, with an ultimate completion date of July 31, 2030. The project, titled "Functional Definition of T Cell Receptors Associated with Protection from Pulmonary TB Infection and Disease," aims to identify and characterize T cell...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $802,418 to The Global Alliance For TB Drug Development Inc. (TB Alliance) on May 7, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports the TB LATITUDE (Long-Acting Treatment Innovation for Tuberculosis Drug Effectiveness) project, which aims to develop long-acting injectable (LAI) formulation technologies for tuberculosis...

Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Boston Children's Hospital $489,500 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop innovative human cellular models for studying tuberculosis (TB) infection and innate immune responses. The award, effective August 1, 2025, through July 31, 2027, funds the establishment of a physiological in vitro lung alveolar epithelial cell organoid model derived...